Our observation suggested that chemotherapy drugs or inhibitor targeting either Akt or EGFR can still be effective to treat advanced prostate cancer even the patient has received androgen ablation therapy for more than 1-2 years. The gene discussed is EGFR; the disease is prostate carcinoma.